Lilly has announced the acquisition of two companies, Curevo and LimmaTech Biologics, to enhance its portfolio in infectious disease prevention. This move aims to tackle the long-term health issues caused by infectious diseases, focusing on prevention rather than just treatment. One of Curevo’s key products is amezosvatein, a new shingles vaccine designed to reduce side effects and improve vaccination rates. This is particularly important as shingles has been linked to increased risks of stroke and dementia.

For people looking to age well, these advancements in vaccine technology could mean better protection against diseases like shingles, which can have serious long-term effects. The new vaccine is engineered to minimize side effects, making it easier for more adults to get vaccinated. This could help lower the incidence of shingles and its associated risks, ultimately contributing to better overall health as you age.

The research behind amezosvatein is promising, having shown effective immune responses in a Phase 2 clinical trial, where it also significantly reduced side effects compared to the current standard of care. LimmaTech is also working on vaccines for bacterial infections that are becoming harder to treat due to rising antibiotic resistance. Their lead program is in Phase 1 development, indicating that while progress is being made, these vaccines are still in the early stages of research.

As these new vaccines become available, staying informed about vaccination options and discussing them with your healthcare provider could be beneficial for your long-term health strategy.

Source: investor.lilly.com